← Back to all trials
Enrolling By Invitation
NCT07948993
VOSE vs. MOSE in EUS-FNB for Pancreatic Masses
Conditions: Pancreatic Neoplasms
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 472
Sponsor: Ruijin Hospital
Location: Ruijin hospital Shanghai Shanghai Municipality
Summary
The primary endpoint of this study was to evaluate whether the histopathological diagnostic accuracy of VOSE EUS-FNB using 22-gauge (22G) Franseen or 22G Trident (Trident™) needles is non-inferior to that of MOSE EUS-FNB in pancreatic solid masses. The secondary endpoints included diagnostic sensitivity, diagnostic specificity, median number of needle passes, puncture time, and cytological diagnostic accuracy.
Eligibility Criteria
Inclusion Criteria:
* Age above 18 years, male or female.
* Presence of a solid pancreatic mass detected by CT, MRI, PET-CT, or EUS, and scheduled for EUS-FNB for diagnostic purposes.
* Provision of signed written informed consent.
Exclusion Criteria:
* Contraindications to endoscopy, such as severe cardiovascular or cerebrovascular diseases.
* Coagulation disorders (International Normalized Ratio \[INR\] ≥ 1.5, platelet count ≤ 50 × 10\^9/L) or current use of anticoagulant or antiplatelet medications.
* Confirmed or suspected pregnancy.
* Pathological diagnosis has already been established by other methods.
* Refusal to participate in the study, current participation in another clinical trial, or participation in another clinical trial within 60 days prior to enrollment.
* Any other conditions that preclude the performance of EUS-FNB.
Source: ClinicalTrials.gov (NCT07948993). StuddyBuddy aggregates publicly available trial information.